Liquidity Agreement and Total Voting Rights

RNS Number : 3968O
Novacyt S.A.
02 October 2023
Â

Â

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Â

Liquidity Agreement Monthly Update and Total Voting Rights

Â

Paris, France and Eastleigh, UK - 2 October 2023 - NovacytÂ (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised below.

Â

During the period from 1 September to 30 September 2023, Invest Securities purchased 115,020 ordinary shares at a maximum price of â,¬0.92 and a minimum price of â,¬0.68 and sold 95,667 ordinary shares at a maximum price of â,¬0.94 and a minimum price of â,¬0.70 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 30 September 2023, is 68,496.

Â

Total Voting Rights

Â

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

Â

Contacts

Â

Novacyt SA	+44 (0) 23 8074 8830
James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer	

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	+44 (0)20 3470 0470 Â
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
Numis (Joint Broker)	+44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Jack McLaren	
Allegra Finance (French Listing Sponsor)	+33 (1) 42 22 10 10
RÃ©mi Durgetto / Yannick Petit	Â r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Anna Dunphy / Phillip Marriage	+44 (0)20 7933 8780 novacyt@walbrookpr.com Â

Â

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

Â

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its RangerÂ® Technology to deliver dynamic target enrichment.

Â

Novacyt is headquartered in VÃ©lizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

Â

For more information, please refer to the website: www.novacyt.com

Â

Further information on the Liquidity Agreement

Â

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

Â

Shareholder approval was granted at the Shareholders' meeting held on 20 July 2022 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of â,¬12.00 for an aggregate maximum purchase price of â,¬200,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid â,¬10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

Â

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Â
END
Â
Â
TVRFLLFBXBLZFBX